ALHEMO

This brand name is authorized in United States. It is also authorized in Lithuania.

Active ingredients

The drug ALHEMO contains one active pharmaceutical ingredient (API):

1	Concizumab UNII 68603V9EAF - CONCIZUMAB
	Concizumab is an anti-tissue factor pathway inhibitor (anti-TFPI) antibody. TFPI is an inhibitor of factor Xa (FXa). Concizumab binding to TFPI prevents TFPI inhibition of FXa. The increased FXa activity prolongs the initiation phase of coagulation and allows sufficient thrombin generation for effective haemostasis. Concizumab acts independently from FVIII and FIX.
	Read more about Concizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ALHEMO Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BX10		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1102109, 1102110, 1102111, 1102112, 1102113, 1102114, 1102115
US	FDA, National Drug Code	0169-2080, 0169-2081, 0169-2084